Vaccine Breakthrough Infections with SARS-CoV-2 Variants - PubMed (original) (raw)
Case Reports
. 2021 Jun 10;384(23):2212-2218.
doi: 10.1056/NEJMoa2105000. Epub 2021 Apr 21.
Caryn Hale 1, Yuhki Saito 1, Nathalie E Blachere 1, Marissa Bergh 1, Erin G Conlon 1, Dennis J Schaefer-Babajew 1, Justin DaSilva 1, Frauke Muecksch 1, Christian Gaebler 1, Richard Lifton 1, Michel C Nussenzweig 1, Theodora Hatziioannou 1, Paul D Bieniasz 1, Robert B Darnell 1
Affiliations
- PMID: 33882219
- PMCID: PMC8117968
- DOI: 10.1056/NEJMoa2105000
Case Reports
Vaccine Breakthrough Infections with SARS-CoV-2 Variants
Ezgi Hacisuleyman et al. N Engl J Med. 2021.
Abstract
Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks previously, we identified 2 women with vaccine breakthrough infection. Despite evidence of vaccine efficacy in both women, symptoms of coronavirus disease 2019 developed, and they tested positive for SARS-CoV-2 by polymerase-chain-reaction testing. Viral sequencing revealed variants of likely clinical importance, including E484K in 1 woman and three mutations (T95I, del142-144, and D614G) in both. These observations indicate a potential risk of illness after successful vaccination and subsequent infection with variant virus, and they provide support for continued efforts to prevent and diagnose infection and to characterize variants in vaccinated persons. (Funded by the National Institutes of Health and others.).
Copyright © 2021 Massachusetts Medical Society.
Figures
Figure 1. Evidence of Vaccine Efficacy in Patient 1.
Panel A shows the results of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudotype neutralization assay in Patient 1. Relative luminescence units (RLUs) normalized to units from unvaccinated persons are shown. The 𝙸 bars indicate 95% confidence intervals. Panel B shows the neutralizing antibody titers in serum obtained from recovered patients 1.3 months and 6.2 months after infection, from persons who had received both doses of either the mRNA-1273 or BNT162b2 vaccine, and from Patient 1 (after vaccination and infection). The 50% neutralization testing (NT50) titer among recovered patients at 1.3 months after infection did not differ significantly from that among persons who received both doses of either mRNA-1273 or BNT162b2 vaccine. The red bars indicate geometric means; high levels of neutralizing activity (mean [±SD] NT50, 3209±760) in Patient 1 are shown. The mean serum neutralizing antibody titers are from three independent experiments, each performed in duplicate. NS denotes not significant.
Figure 2. Phylogenetic Tree.
In the clade analysis for Patient 1, the closest match was between clades 20B and 20C. The SARS-CoV-2 variant first identified in the United Kingdom (B.1.1.7) is clade B, and the variant first identified in New York City (B.1.526) is clade 20C.
Figure 3. Phylogenetic Comparisons of SARS-CoV-2 Variants.
The red line indicates Patient 1.
Figure 4. Neutralization Assays for Antibodies to the Wuhan-Hu-1 Isolate, the E484K Variant, and the B.1.526 Variant.
Pseudotype neutralization assays for the wild-type (Wuhan-Hu-1 isolate) virus, the E484K mutant, and the B.1.526 variant first identified in New York City (including the substitutions L5F, T95I, D253G, E484K, D614G, and A701V) were performed with a serum sample obtained from Patient 1. Shown are means and standard deviations (𝙸 bars) of three independent experiments. The E484K substitution alone or together with other substitutions in the B.1.526 variant were not significantly more resistant to neutralization by the serum from Patient 1 than the wild-type virus.
Comment in
- Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
Nixon DF, Ndhlovu LC. Nixon DF, et al. N Engl J Med. 2021 Jul 8;385(2):e7. doi: 10.1056/NEJMc2107808. Epub 2021 Jun 2. N Engl J Med. 2021. PMID: 34077640 No abstract available. - Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
Rana K, Mohindra R, Pinnaka L. Rana K, et al. N Engl J Med. 2021 Jul 8;385(2):e7. doi: 10.1056/NEJMc2107808. Epub 2021 Jun 2. N Engl J Med. 2021. PMID: 34077641 No abstract available. - Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine.
Ulhaq ZS, Soraya GV, Indriana K. Ulhaq ZS, et al. Indian J Med Microbiol. 2021 Oct-Dec;39(4):562-563. doi: 10.1016/j.ijmmb.2021.05.017. Epub 2021 Jun 4. Indian J Med Microbiol. 2021. PMID: 34099338 Free PMC article. No abstract available. - Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers.
Lange B, Gerigk M, Tenenbaum T. Lange B, et al. N Engl J Med. 2021 Sep 16;385(12):1145-1146. doi: 10.1056/NEJMc2108076. Epub 2021 Aug 18. N Engl J Med. 2021. PMID: 34407332 Free PMC article. No abstract available.
Similar articles
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA, Oliveira TY, Yang Z, Abernathy ME, Huey-Tubman KE, Hurley A, Turroja M, West KA, Gordon K, Millard KG, Ramos V, Da Silva J, Xu J, Colbert RA, Patel R, Dizon J, Unson-O'Brien C, Shimeliovich I, Gazumyan A, Caskey M, Bjorkman PJ, Casellas R, Hatziioannou T, Bieniasz PD, Nussenzweig MC. Wang Z, et al. Nature. 2021 Apr;592(7855):616-622. doi: 10.1038/s41586-021-03324-6. Epub 2021 Feb 10. Nature. 2021. PMID: 33567448 Free PMC article. - SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
Forgacs D, Jang H, Abreu RB, Hanley HB, Gattiker JL, Jefferson AM, Ross TM. Forgacs D, et al. Front Immunol. 2021 Sep 27;12:728021. doi: 10.3389/fimmu.2021.728021. eCollection 2021. Front Immunol. 2021. PMID: 34646267 Free PMC article. - Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
Collier AY, McMahan K, Yu J, Tostanoski LH, Aguayo R, Ansel J, Chandrashekar A, Patel S, Apraku Bondzie E, Sellers D, Barrett J, Sanborn O, Wan H, Chang A, Anioke T, Nkolola J, Bradshaw C, Jacob-Dolan C, Feldman J, Gebre M, Borducchi EN, Liu J, Schmidt AG, Suscovich T, Linde C, Alter G, Hacker MR, Barouch DH. Collier AY, et al. JAMA. 2021 Jun 15;325(23):2370-2380. doi: 10.1001/jama.2021.7563. JAMA. 2021. PMID: 33983379 Free PMC article. - Homologous and Heterologous Covid-19 Booster Vaccinations.
Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek JA, Dominguez Islas CP, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH; DMID 21-0012 Study Group. Atmar RL, et al. N Engl J Med. 2022 Mar 17;386(11):1046-1057. doi: 10.1056/NEJMoa2116414. Epub 2022 Jan 26. N Engl J Med. 2022. PMID: 35081293 Free PMC article. Clinical Trial. - Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.
Noori M, Nejadghaderi SA, Arshi S, Carson-Chahhoud K, Ansarin K, Kolahi AA, Safiri S. Noori M, et al. Rev Med Virol. 2022 Mar;32(2):e2277. doi: 10.1002/rmv.2277. Epub 2021 Jul 19. Rev Med Virol. 2022. PMID: 34286893 Free PMC article. Review.
Cited by
- COVID-19 infection after vaccination.
Baziboroun M, Hosseinzadeh S, Gholinia H, Sadeghi F, Yahyapour Y. Baziboroun M, et al. Caspian J Intern Med. 2024 Aug 30;15(4):644-650. doi: 10.22088/cjim.15.4.644. eCollection 2024 Fall. Caspian J Intern Med. 2024. PMID: 39359433 Free PMC article. - Elucidating the Immune Response to SARS-CoV-2: Natural Infection versus Covaxin/Covishield Vaccination in a South Indian Population.
Vanamudhu A, Devi Arumugam R, Nancy A, Selvaraj N, Moiden K, Hissar S, Ranganathan UD, Bethunaickan R, Babu S, Kumar NP. Vanamudhu A, et al. Viruses. 2024 Jul 23;16(8):1178. doi: 10.3390/v16081178. Viruses. 2024. PMID: 39205152 Free PMC article. - Advances in the study of LNPs for mRNA delivery and clinical applications.
Wang B, Shen B, Xiang W, Shen H. Wang B, et al. Virus Genes. 2024 Aug 22. doi: 10.1007/s11262-024-02102-6. Online ahead of print. Virus Genes. 2024. PMID: 39172354 Review. - Incidence and risk factors of SARS-CoV-2 breakthrough infection in the early Omicron variant era among vaccinated and boosted individuals in Chicago.
Moreno Echevarria F, Caputo M, Camp D, Reddy S, Achenbach CJ. Moreno Echevarria F, et al. PLoS One. 2024 Aug 5;19(8):e0302338. doi: 10.1371/journal.pone.0302338. eCollection 2024. PLoS One. 2024. PMID: 39102410 Free PMC article. - Effectiveness and duration of additional immune defense provided by SARS-CoV-2 infection before and after receiving the mRNA COVID-19 vaccine BNT162b2.
Shimada N, Sugawa S, Murakami S, Shinoda M, Ota S, Morikawa M, Takei H, Serizawa Y, Takahashi H, Toyama-Kousaka M, Matsuse H, Shinkai M. Shimada N, et al. Vaccine X. 2024 Jun 26;19:100518. doi: 10.1016/j.jvacx.2024.100518. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39040888 Free PMC article.
References
- NYC Health. New York City COVID-19 cases caused by SARS-CoV-2 variants report. March 2021. (https://www1.nyc.gov/assets/doh/downloads/pdf/covid/covid-19-data-varian...).
- Frank MO, Blachere NE, Parveen S, et al. DRUL for school: opening pre-K with safe, simple, sensitive saliva testing for SARS-CoV-2. April 16, 2021. (https://www.medrxiv.org/content/10.1101/2021.04.03.21254873v1). preprint. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 AI138938/AI/NIAID NIH HHS/United States
- R01 AI050111/AI/NIAID NIH HHS/United States
- R01 AI078788/AI/NIAID NIH HHS/United States
- R35 NS097404/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous